We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$45.1M
1-Year Est. Return
74.25%
This Fund
S&P 500
This Quarter
Est. Return
-5.44%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.92B
AUM Growth
-$82.3M
(-4.1%)
Cap. Flow
-$215M
Cap. Flow
% of AUM
-11.22%
Top 10 Holdings %
Top 10 Hldgs %
52.67%
Holding
387
New
94
Increased
95
Reduced
80
Closed
99
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$12.5M |
| 2 |
Abbott
ABT
|
+$10.5M |
| 3 |
Outlook Therapeutics
OTLK
|
+$7.71M |
| 4 |
BPTH
Bio-Path Holdings Inc
BPTH
|
+$7.56M |
| 5 |
SHPG
Shire pic
SHPG
|
+$5.34M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$22.6M |
| 2 |
Biogen
BIIB
|
+$7.14M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$3.88M |
| 4 |
Neurocrine Biosciences
NBIX
|
+$3.22M |
| 5 |
ESRX
Express Scripts Holding Company
ESRX
|
+$2.84M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 12.85% |
| 2 | Industrials | 0.12% |
| 3 | Consumer Staples | 0.07% |
| 4 | Consumer Discretionary | 0.06% |
| 5 | Technology | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
Eli Lilly
LLY
$1.09T
| $237M | 12.38% |
30,121
+1,159
| +4% | +$87.3K |
|
|
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$783B
| $176M | 9.2% |
8,415
-1,761
| -17% | -$365K |
|
3
PUT
iShares S&P 100 ETF
OEF
$19.8B
| $156M | 8.16% |
13,600
-4,073
| -23% | -$376K |
|
4
CALL
AbbVie
ABBV
$465B
| $111M | 5.82% |
18,007
+4,041
| +29% | +$246K |
|
5
CALL
HCA Healthcare
HCA
$92.8B
| $71.5M | 3.73% |
9,291
+2,493
| +37% | +$197K |
|
6
PUT
Amgen
AMGN
$212B
| $60M | 3.13% |
3,942
+501
| +15% | +$77.9K |
|
7
PUT
Sarepta Therapeutics
SRPT
$1.63B
| $55.8M | 2.91% |
29,250
+20,426
| +231% | +$378K |
|
|
MON
8
CALL
DELISTED
Monsanto Co
MON
| $55.2M | 2.88% |
+5,334
| New | +$528K |
|
|
9
CALL
Biogen
BIIB
$30.4B
| $45.1M | 2.35% |
1,866
-4,797
| -72% | -$1.26M |
|
|
10
PUT
Regeneron Pharmaceuticals
REGN
$72.9B
| $40.5M | 2.11% |
1,160
+572
| +97% | +$220K |
|
|
11
PUT
Eli Lilly
LLY
$1.09T
| $38.5M | 2.01% |
4,891
+88
| +2% | +$6.63K |
|
12
CALL
Pfizer
PFE
$144B
| $35.2M | 1.84% |
+10,540
| New | +$336K |
|
13
CALL
Johnson & Johnson
JNJ
$643B
| $34.1M | 1.78% |
2,809
-3,565
| -56% | -$405K |
|
14
PUT
DexCom
DXCM
$28.9B
| $33.4M | 1.74% |
+16,856
| New | +$287K |
|
|
15
CALL
Sarepta Therapeutics
SRPT
$1.63B
| $29M | 1.51% |
15,225
+14,032
| +1,176% | +$260K |
|
|
16
Regeneron Pharmaceuticals
REGN
$72.9B
| $25M | 1.3% |
71,525
+32,498
| +83% | +$12.5M |
|
|
17
Amgen
AMGN
$212B
| $23.4M | 1.22% |
154,082
+10,596
| +7% | +$1.65M |
|
|
18
PUT
Abbott
ABT
$187B
| $19.7M | 1.03% |
+5,000
| New | +$199K |
|
19
PUT
MannKind Corp
MNKD
$1.21B
| $18.3M | 0.95% |
10,596
+10,377
| +4,738% | +$64.2K |
|
20
CALL
Teva Pharmaceuticals
TEVA
$36.9B
| $18.2M | 0.95% |
+3,618
| New | +$193K |
|
|
TSRO
21
CALL
DELISTED
TESARO, Inc.
TSRO
| $18.1M | 0.95% |
+2,158
| New | +$96.2K |
|
22
CALL
Travere Therapeutics
TVTX
$5.2B
| $16.8M | 0.88% |
9,445
+5,828
| +161% | +$94.3K |
|
|
DVAX
23
CALL
DELISTED
Dynavax Technologies
DVAX
| $15.6M | 0.81% |
10,712
+9,412
| +724% | +$161K |
|
24
CALL
Acadia Pharmaceuticals
ACAD
$4.45B
| $15.2M | 0.79% |
4,674
+2,834
| +154% | +$94.8K |
|
|
25
Sarepta Therapeutics
SRPT
$1.63B
| $14.9M | 0.78% |
783,497
+277,560
| +55% | +$5.14M |
|
Similar funds
CG
OC
ICCON
PCM
CAS
CM
MCMC
CTC
Sabby Management's Q2 2016 Portfolio in Review
As of Q2 2016, Sabby Management held 387 positions worth $1.92B, down 4.1% from $2B the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Sabby Management withdrew a net $215M in Q2 2016, closing 99 positions and reducing 80 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $22.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 12% a quarter earlier, followed by Industrials and Consumer Staples.
Against the trend, Sabby Management opened a new position in Abbott worth $10.4M.
- Sabby Management's largest Q2 2016 buy was Abbott: 264,700 shares worth $10.4M.
- Sabby Management added most to Regeneron Pharmaceuticals in Q2 2016, an estimated $12.5M increase.
- Sabby Management's biggest Q2 2016 reduction was Biogen, cutting an estimated $7.14M.
- Sabby Management fully exited State Street SPDR S&P 500 ETF Trust in Q2 2016, selling an estimated $22.6M.
- Sabby Management's ten largest holdings make up 53% of its $1.92B portfolio in Q2 2016.
- Sabby Management opened 94 new positions and closed 99 in Q2 2016.
- Sabby Management's portfolio value fell 4.1% quarter-over-quarter to $1.92B.
Based on Sabby Management's 13F filing for Q2 2016, filed 15 Aug 2016.